# EDGAR Filing Document

**Accession Number:** 0000790526
**File Stem:** 0001683168-26-003624
**Filing Date:** 2026-5
**Character Count:** 45345
**Document Hash:** 4a74c3f115dc7fa5f32259aa33bdf385
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001683168-26-003624.hdr.sgml**: 20260511

**ACCESSION NUMBER**: 0001683168-26-003624

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20260510

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260511

**DATE AS OF CHANGE**: 20260511

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** RadNet, Inc.
- **CENTRAL INDEX KEY:** 0000790526
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-MEDICAL LABORATORIES [8071]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 133326724
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-33307
- **FILM NUMBER:** 26960863

**BUSINESS ADDRESS:**
- **STREET 1:** 1510 COTNER AVE
- **CITY:** LOS ANGELES
- **STATE:** CA
- **ZIP:** 90025
- **BUSINESS PHONE:** 3104787808

**MAIL ADDRESS:**
- **STREET 1:** 1510 COTNER AVE
- **CITY:** LOS ANGELES
- **STATE:** CA
- **ZIP:** 90025

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** PRIMEDEX HEALTH SYSTEMS INC
- **DATE OF NAME CHANGE:** 19930518

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CCC FRANCHISING CORP
- **DATE OF NAME CHANGE:** 19920703

?xml version='1.0' encoding='ASCII'? RadNet, Inc. 8-K

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported) **May 10, 2026**

**RadNet, Inc.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;**Delaware** | &nbsp;&nbsp;&nbsp;**001-33307** | **13-3326724** |
| &nbsp;&nbsp;&nbsp;(State or other jurisdiction of incorporation) | &nbsp;&nbsp;&nbsp;(Commission File Number) | (IRS Employer Identification No.) |

---

---

| |
|:---|
| **1510 Cotner Avenue** |
| **Los Angeles, California 90025** |
| (Address of Principal Executive Offices) (ZipCode) |

---

 **(310) 478-7808**

(Registrant's Telephone Number, Including Area Code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, $0.0001 par value | RDNT | NASDAQ |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

---

| | |
|:---|:---|
| **Item 2.02** | **RESULTS OF OPERATIONS AND FINANCIAL CONDITION** |

---

On May 10, 2026 RadNet, Inc. ("RadNet") issued a press release regarding its financial results for the first quarter ended March 31, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

---

| | |
|:---|:---|
| **Item 9.01** | **FINANCIAL STATEMENTS AND EXHIBITS** |

---

(d) Exhibits

---

| | |
|:---|:---|
| **Exhibit Number** | **Description of Exhibit** |
| 99.1 | [Press Release dated May 10, 2026 relating to RadNet, Inc.'s financial results for the quarter ended March 31, 2026](radnet_ex9901.htm). |
| 104 | Cover Page Interactive Data File (embedded within the inline XBRL document). |

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Date: May 11, 2026 | **RADNET, INC.** | **RADNET, INC.** |
|  | By: | /s/ Mark D. Stolper |
|  | Name: | Mark D. Stolper |
|  | Title: | Chief Financial Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

FOR IMMEDIATE RELEASE

**RadNet Reports Record First Quarter Financial Results and Revises Upwards 2026 Imaging Center Financial Guidance Ranges for Revenue, Adjusted EBITDA and Free Cash Flow**

· *Total Company Revenue increased 22.1% to $575.6 million in the first quarter of 2026 from $471.4 million in the first quarter of 2025* 

· *Revenue from the Digital Health reportable segment increased 51.5% to $29.1 million in the first quarter of 2026 from $19.2 million in the first quarter of 2025; Annual Recurring Revenue<sup>(4)</sup> (ARR) increased from $49.8 million at March 31, 2025 to $96.9 million at March 31, 2026* 

· *Total Company Adjusted EBITDA<sup>(1)</sup>was $63.3 million in the first quarter of 2026 as compared with $46.4 million in the first quarter of 2025, an increase of 36.3%; Digital Health reportable segment Adjusted EBITDA<sup>(1)</sup> decreased to $1.3 million in the first quarter of 2026 from $3.7 million in the first quarter of 2025 resulting from continued intentional infrastructure investments to drive and support a growing sales pipeline* 

· *In the first quarter of 2026, aggregate advanced imaging (MRI, CT and PET/CT) procedural volumes increased 19.7% and same-center advanced imaging procedural volumes increased 8.2% as compared with the first quarter of 2025* 

· *Adjusting for unusual or one-time items in the quarter, Adjusted Diluted Loss Per Share<sup>(3)</sup> was $(0.28) for the first quarter of 2026; This compares with Adjusted Diluted Loss Per Share<sup>(3)</sup> of $(0.34) for the first quarter of 2025* 

· *RadNet revises full-year 2026 Imaging Center guidance levels with increases to Revenue, Adjusted EBITDA<sup>(1)</sup> and Free Cash Flow<sup>(2)</sup> and reaffirms all Digital Health guidance ranges<br>* 

<br> **LOS ANGELES, California, May 10, 2026 – RadNet, Inc. (NASDAQ: RDNT),** a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services through a network of 435 outpatient imaging centers and a premier developer of radiology digital health solutions, today reported financial results for its first quarter of 2026.

Dr. Howard Berger, President and Chief Executive Officer of RadNet, commented, "After being impacted by severe winter weather conditions in the Northeast during January and February which reduced Revenue and Adjusted EBITDA<sup>(1)</sup> by an estimated $13 million and $9 million, respectively, our business strongly rebounded in March, resulting in a Total Company Revenue increase of 22.1% and a Total Company Adjusted EBITDA<sup>(1)</sup> increase of 36.3% from last year's first quarter. The record first quarter performance was driven by aggregate advanced imaging (MRI, CT and PET/CT) growth of 19.7% and same-center advanced imaging growth of 8.2% as compared with the first quarter of last year. The growth in MR, CT and PET/CT contributed to a 235 basis point shift in RadNet's advanced imaging procedural volume mix (relative to routine imaging) as compared with the same quarter last year, increasing from 26.9% in last year's first quarter to 29.3% in the first quarter of 2026. Imaging Center Adjusted EBITDA<sup>(1)</sup> margin increased by 52 basis points, after adjusting for lost Revenue and Adjusted EBITDA<sup>(1)</sup> from the severe winter weather in this year's first quarter and the severe winter weather and California wildfires in last year's first quarter."

Dr. Berger continued, "On April 30th, we announced the commencement of a new health system joint venture with Trinity Health's Saint Alphonsus Health System initially with five outpatient imaging centers in Boise, Idaho. In conjunction with this new partnership, various modules of DeepHealth OS as well as AI-powered solutions for radiologist reporting, patient engagement and clinical interpretation will be implemented. This relationship is a blueprint for future health system partnerships, where RadNet can bring all of its operational, clinical and digital workflow solutions to bear to streamline the patient journey and improve medical care and outcomes. As a result of the strong operating trends during the first quarter which have continued through early May, we are increasing 2026 Imaging Center guidance for Revenue, Adjusted EBITDA<sup>(1)</sup> and Free Cash Flow<sup>(2)</sup>."

"The Digital Health division continues to gain momentum, which was further advanced with the March 2, 2026 acquisition of Gleamer SAS in France. DeepHealth's clinical AI portfolio now includes interpretive solutions in virtually all imaging modalities. We estimate that by the end of this year, over 70% of RadNet studies could be running through clinical AI, and we expect that all of RadNet's radiologist reports will be processed through DeepHealth's Reporting Pro AI-powered auto-impression/summarization engine. When fully implemented, these initiatives should result in significant enhancement to patient care and workflow productivity intended to achieve a measurable improvement to RadNet's operating expenses. Furthermore, the Digital Health sales pipeline with third-party customers continued to build during the first quarter, during which we signed over $16 million (Total Contract Value) of new DeepHealth business. These contracts span the full breadth of DeepHealth products including clinical AI, operating and diagnostic workflow and TechLive solutions," added Dr. Berger.

"RadNet's balance sheet continues to be among the strongest in the diagnostic imaging industry. At quarter end, which reflected the acquisition of Gleamer and recent imaging center transactions, we had a cash balance of $455.3 million and a leverage ratio of Net Debt to Adjusted EBITDA<sup>(1)</sup> of slightly below 2.0. Financial leverage and liquidity will continue to be carefully managed to maintain optimal future operating flexibility," concluded Dr. Berger.

**<u>Financial Results</u>**

 

For the first quarter of 2026, RadNet reported Total Company Revenue of $575.6 million and Adjusted EBITDA<sup>(1)</sup> of $63.3 million. Revenue increased $104.2 million (or 22.1%) and Adjusted EBITDA<sup>(1)</sup> increased $16.9 million (or 36.3%) as compared with the first quarter of 2025.

For the first quarter of 2026, RadNet reported Digital Health Revenue (inclusive of intersegment revenue) of $29.1 million and Adjusted EBITDA<sup>(1)</sup> of $1.3 million. Revenue increased $9.9 million (or 51.5%) and Adjusted EBITDA<sup>(1)</sup> decreased $2.4 million as compared with the first quarter of 2025. At March 31, 2026, Annual Recurring Revenue<sup>(4)</sup> (ARR) for Digital Health was $96.9 million, as compared with $49.8 million as of March 31, 2025.

There were a number of unusual or one-time items impacting the first quarter including: $0.9 million expense related to leases for de novo facilities under construction that have yet to open their operations; $3.5 million of acquisition transaction costs; $2.6 million loss on the sale and disposal of equipment; $1.5 million of severance costs; $2.8 million change in contingent consideration related to past acquisitions; and $4.6 million of non-capitalized research and development expenses with respect to DeepHealth Cloud OS and generative AI. Adjusting for the above items, Total Company Adjusted Loss<sup>(3)</sup> was $21.6 million and diluted Adjusted Loss Per Share<sup>(3)</sup> was $(0.28) for the first quarter of 2026. This compares with Total Company Adjusted Loss<sup>(3)</sup> of $25.2 million and diluted Adjusted Loss Per Share<sup>(3)</sup> of $(0.34) during the first quarter of 2025.

Unadjusted for unusual or one-time items impacting the first quarter of 2026, Total Company Net Loss for the first quarter of 2026 was $33.5 million as compared with a Total Company Net Loss of $37.9 million for the first quarter of 2025. Net Loss Per Share for the first quarter of 2026 was $(0.43), compared with a Net Loss per share of $(0.51) in the first quarter of 2025, based upon a weighted average number of diluted shares outstanding of 77.1 million shares in 2026 and 74.4 million shares in 2025.

For the first quarter of 2026, as compared with the prior year's first quarter, MRI volume increased 20.3%, CT volume increased 17.7% and PET/CT volume increased 35.2% on a systemwide basis (including unconsolidated joint venture centers). Overall volume, taking into account routine imaging exams, inclusive of x-ray, ultrasound, mammography and other exams, increased 10.1% over the prior year's first quarter. On a same-center systemwide basis, including only those centers which were part of RadNet for both the first quarters of 2026 and 2025, MRI volume increased 10.0%, CT volume increased 4.7% and PET/CT volume increased 14.7%. Overall same-center volume, taking into account routine imaging exams, inclusive of x-ray, ultrasound, mammography and other exams, increased 2.4% over the prior year's same quarter.

**<u>2026 Revised Guidance</u>**

RadNet amends its previously announced guidance levels as follows:

<u>Imaging Center Segment</u>

---

| | | |
|:---|:---|:---|
|  | Original Guidance Range | Revised Guidance Range |
| Total Net Revenue | $2,325 - $2,375 million | $2,355 - $2,405 million |
| Adjusted EBITDA<sup>(1)</sup> | $335 - $348 million | $340 - $353 million |
| Capital Expenditures<sup>(a)</sup> | $165 - $175 million | $165 - $175 million |
| Cash Interest Expense<sup>(b)</sup> | $45 - $50 million | $45 - $50 million |
| Free Cash Flow<sup>(2)</sup> | $105 - $115 million | $112 - $122 million |

---

&nbsp;&nbsp;&nbsp;&nbsp;(a) Net of proceeds from the sale of equipment and New Jersey Imaging Network capital expenditures.

&nbsp;&nbsp;&nbsp;&nbsp;(b) Net of payments from counterparties on interest rate swaps and interest income from our cash balance recorded
in Other Income.

<u>Digital Health Segment</u>

---

| | | |
|:---|:---|:---|
|  | Original Guidance Range | Revised Guidance Range |
| Total Net Revenue | $135 - $145 million | $135 - $145 million |
| Adjusted EBITDA<sup>(1)</sup> Before Non-Capitalized R&D - DeepHealth Cloud OS & Generative AI | $10 - $12 million | $10 - $12 million |
| Non-Capitalized R&D - DeepHealth Cloud OS & Generative AI | $17 - $19 million | $17 - $19 million |
| Capital Expenditures | $9 - $12 million | $9 - $12 million |
| Free Cash Flow<sup>(2)</sup> Before Non-Capitalized R&D - DeepHealth Cloud OS & Generative AI | $(1) - $3 million | $(1) - $3 million |
| Free Cash Flow<sup>(2)</sup> After Non-Capitalized R&D - DeepHealth Cloud OS & Generative AI | $(17) - $(19) million | $(17) - $(19) million |

---

**<u>Financial Results Conference Call</u>**

Dr. Howard Berger, President and Chief Executive Officer, and Mark Stolper, Executive Vice President and Chief Financial Officer, will host a conference call to discuss its first quarter 2026 results on Monday, May 11th, 2026 at 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time).

*Conference Call Details:*

Date: Monday, May 11, 2026

Time: 10:30 a.m. Eastern Time

Dial In-Number: 844-744-1280

International Dial-In Number: 412-564-6465

It is recommended that participants dial in approximately 5 to 10 minutes prior to the start of the 10:30 a.m. call. There will also be simultaneous and archived webcasts available at https://viavid.webcasts.com/starthere.jsp?ei=1761306&tp_key=ea5d61284c or http://www.radnet.com under the "Investors" menu section and "News Releases" sub-menu of the website. An archived replay of the call will also be available and can be accessed by dialing 844-512-2921 from the U.S., or 412-317-6671 for international allers, and using the passcode 10208825.

 **

 ****

***About RadNet, Inc.***

 **

RadNet, Inc. is a leading national provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue. RadNet has a network of owned and/or operated outpatient imaging centers. RadNet's imaging center markets include Arizona, California, Delaware, Florida, Idaho, Indiana, Maryland, New Jersey, New York, Texas and Virginia. In addition, RadNet provides radiology information technology and artificial intelligence solutions marketed under the DeepHealth brand, teleradiology professional services and other related products and services to customers in the diagnostic imaging industry globally. Together with contracted radiologists, and inclusive of full-time and per diem employees and technologists, RadNet has over 11,000 team members. Learn more at radnet.com.

***Forward Looking Statements***

 ****

This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are expressions of our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, and anticipated future conditions, events and trends. Forward-looking statements can generally be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods.

Forward-looking statements are neither historical facts nor assurances of future performance. Because forward-looking statements relate to the future, they are inherently subject to uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not place undue reliance on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following:

&nbsp;&nbsp;&nbsp;&nbsp;· the impact of a pandemic, significant deterioration
in the broader economy, severe acts of nature or other exogenous factors on our business, suppliers, payors, customers, referral sources,
partners, patients and employees;

&nbsp;&nbsp;&nbsp;&nbsp;· the availability and terms of capital to fund
our business;

&nbsp;&nbsp;&nbsp;&nbsp;· our ability to service our indebtedness, make
principal and interest payments as those payments become due and remain in compliance with applicable debt covenants, in addition to our
ability to refinance such indebtedness on acceptable terms;

&nbsp;&nbsp;&nbsp;&nbsp;· changes in general economic conditions nationally
and regionally in the markets in which we operate;

&nbsp;&nbsp;&nbsp;&nbsp;· the availability and terms of capital to fund
the expansion of our business and improvements to our existing facilities;

&nbsp;&nbsp;&nbsp;&nbsp;· our ability to maintain our current credit rating
and the impact on our funding costs and competitive position if we do not do so;

&nbsp;&nbsp;&nbsp;&nbsp;· our ability to acquire, develop, implement and monetize artificial intelligence algorithms and applications;

&nbsp;&nbsp;&nbsp;&nbsp;· volatility in interest and exchange rates, or
credit markets;

&nbsp;&nbsp;&nbsp;&nbsp;· the adequacy of our cash flow and earnings to
fund our current and future operations;

&nbsp;&nbsp;&nbsp;&nbsp;· changes in service mix, revenue mix and procedure
volumes;

&nbsp;&nbsp;&nbsp;&nbsp;· delays in receiving payments for services provided;

&nbsp;&nbsp;&nbsp;&nbsp;· increased bankruptcies among our partner physicians
or joint venture partners;

&nbsp;&nbsp;&nbsp;&nbsp;· the impact of the political environment and related
developments on the current healthcare marketplace and on our business, including with respect to the future of the Affordable Care Act;

&nbsp;&nbsp;&nbsp;&nbsp;· the extent to which the ongoing implementation
of healthcare reform, or changes in or new legislation, regulations or guidance, enforcement thereof by federal and state regulators or
related litigation result in a reduction in coverage or reimbursement rates for our services, or other material impacts to our business;

&nbsp;&nbsp;&nbsp;&nbsp;· closures or slowdowns and changes in labor costs
and labor difficulties, including stoppages affecting either our operations or our suppliers' abilities to deliver supplies needed in
our facilities;

&nbsp;&nbsp;&nbsp;&nbsp;· the occurrence of hostilities, political instability
or catastrophic events;

&nbsp;&nbsp;&nbsp;&nbsp;· the emergence or reemergence of and effects related
to future pandemics, epidemics and infectious diseases; and

&nbsp;&nbsp;&nbsp;&nbsp;· noncompliance by us with any privacy or security
laws or any cybersecurity incident or other security breach by us or a third party involving the misappropriation, loss or other unauthorized
use or disclosure of confidential information.

&nbsp;&nbsp;&nbsp;&nbsp;· With respect to mergers and acquisitions: (1) the termination of or occurrence of any event, change or other circumstances that could
give rise to the termination of the merger or acquisition agreement or the inability to complete the proposed transaction on the anticipated
terms and timetable, (2) the inability to complete the proposed transaction due to any applicable regulatory approval that may be required
for the proposed transaction that is delayed, that is not obtained or that is obtained subject to conditions that are not anticipated,
(3) the ability to recognize the anticipated benefits of the proposed transaction, which may be affected by, among other things, the ability
to maintain relationships with its customers, patients, payers, physicians, and providers and retain its management and key employees,
(4) the ability of RadNet following the proposed transaction to achieve the synergies contemplated by the proposed transaction or such
synergies taking longer to realize than expected, (5) costs related to the proposed transaction, (6) the ability of RadNet following the
proposed transaction to execute successfully its strategic plans, (7) the ability of RadNet following the proposed transaction to promptly
and effectively integrate the target into its business, (8) the risk of litigation related to the proposed transaction, (9) the diversion
of management's time and attention from ordinary course business operations to completion of the proposed transaction and integration
matters, (10) the risk of legislative, regulatory, economic, competitive, and technological changes, (11) risks relating to the value
of RadNet's securities to be issued in the proposed merger, and (12) the effect of the announcement, pendency or completion of the proposed
transactions on the market price of RadNet's common stock.

The foregoing review of important factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included elsewhere. Additional information concerning risks, uncertainties and assumptions can be found in RadNet's filings with the SEC, including the risk factors discussed in RadNet's most recent Annual Report on Form 10-K, as updated by its Quarterly Reports on Form 10-Q and future filings with the SEC.

Any forward-looking statement contained in this release is based on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that we may make from time to time, whether as a result of changed circumstances, new information, future developments or otherwise, except as required by applicable law.

***Regulation G: GAAP and Non-GAAP Financial Information***

This release contains certain financial information not reported in accordance with GAAP. The Company uses both GAAP and non-GAAP metrics to measure its financial results. The Company believes that, in addition to GAAP metrics, these non-GAAP metrics assist the Company in measuring its cash-based performance. The Company believes this information is useful to investors and other interested parties because it removes unusual and nonrecurring charges that occur in the affected period and provides a basis for measuring the Company's financial condition against other quarters. Such information should not be considered as a substitute for any measures calculated in accordance with GAAP, and may not be comparable to other similarly titled measures of other companies. Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. Reconciliation of this information to the most comparable GAAP measures is included in this release in the tables which follow.

 **

***CONTACTS:***

 

***RadNet, Inc.***

***Mark Stolper, 310-445-2800***

***Executive Vice President and Chief Financial Officer***

 ****

 

 **

 ****

**RADNET, INC. AND SUBSIDIARIES**

**CONDENSED CONSOLIDATED BALANCE SHEETS**

**(IN THOUSANDS EXCEPT SHARE AND PER SHARE DATA)**

---

| | | |
|:---|:---|:---|
|  | **March 31, 2026** | **December 31, 2025** |
|  | **(unaudited)** | |
| **ASSETS** |  |  |
| **CURRENT ASSETS** |  |  |
| &nbsp;&nbsp;&nbsp;Cash and Cash equivalents | $455339 | $767215 |
| &nbsp;&nbsp;&nbsp;Accounts receivable | 209090 | 200317 |
| &nbsp;&nbsp;&nbsp;Due from affiliates | 11033 | 12592 |
| &nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | 65313 | 52003 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets | 740775 | 1032127 |
| **PROPERTY, EQUIPMENT AND RIGHT-OF-USE ASSETS** |  |  |
| &nbsp;&nbsp;&nbsp;Property and equipment, net | 862057 | 807702 |
| &nbsp;&nbsp;&nbsp;Operating lease right-of-use assets | 760975 | 690250 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total property, plant, equipment and right-of-use assets | 1623032 | 1497952 |
| **OTHER ASSETS** |  |  |
| &nbsp;&nbsp;&nbsp;Goodwill | 1094699 | 907663 |
| &nbsp;&nbsp;&nbsp;Other intangible assets | 253481 | 148508 |
| &nbsp;&nbsp;&nbsp;Deferred financing costs | 1538 | 1684 |
| &nbsp;&nbsp;&nbsp;Investment in joint ventures | 131409 | 130340 |
| &nbsp;&nbsp;&nbsp;Deposits and other | 40455 | 40289 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Assets | $3885389 | $3758563 |
| **LIABILITIES AND EQUITY** |  |  |
| **CURRENT LIABILITIES** |  |  |
| &nbsp;&nbsp;&nbsp;Accounts payable, accrued expenses and other | $454602 | $422029 |
| &nbsp;&nbsp;&nbsp;Due to affiliates | 75960 | 70104 |
| &nbsp;&nbsp;&nbsp;Deferred revenue | 11975 | 7272 |
| &nbsp;&nbsp;&nbsp;Current operating lease liability | 66591 | 61934 |
| &nbsp;&nbsp;&nbsp;Current portion of notes payable | 26506 | 25424 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | 635634 | 586763 |
| **LONG-TERM LIABILITIES** |  |  |
| &nbsp;&nbsp;&nbsp;Long-term finance lease liability | 4016 |  |
| &nbsp;&nbsp;&nbsp;Long-term operating lease liability | 777268 | 707001 |
| &nbsp;&nbsp;&nbsp;Notes payable, net of current portion | 1059977 | 1064495 |
| &nbsp;&nbsp;&nbsp;Deferred tax liability, net | 34150 | 21903 |
| &nbsp;&nbsp;&nbsp;Other non-current liabilities | 21632 | 22515 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities | 2532677 | 2402677 |
| **EQUITY** |  |  |
| RadNet, Inc. stockholders' equity: |  |  |
| &nbsp;&nbsp;&nbsp;Common stock - $0.0001 value, 200,000,000 shares authorized; 78,545,837 and 77,399,615 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively | 8 | 8 |
| &nbsp;&nbsp;&nbsp;Additional paid-in-capital | 1211912 | 1180434 |
| &nbsp;&nbsp;&nbsp;Accumulated other comprehensive loss | (2466) | 4885 |
| &nbsp;&nbsp;&nbsp;Accumulated deficit | (128903) | (95437) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total RadNet, Inc.'s Stockholders' equity: | 1080551 | 1089890 |
| &nbsp;&nbsp;&nbsp;Noncontrolling interests | 272161 | 265996 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Equity | 1352712 | 1355886 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities and equity | $3885389 | $3758563 |

---

**RADNET, INC. AND SUBSIDIARIES**

**CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS**

**(IN THOUSANDS EXCEPT FOR SHARE AND PER SHARE DATA)**

(unaudited)

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
|  | **2026** | **2025** |
| **REVENUE** |  |  |
| &nbsp;&nbsp;&nbsp;Service fee revenue | $545218 | $439349 |
| &nbsp;&nbsp;&nbsp;Revenue under capitation arrangements | 30413 | 32050 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total service revenue | 575631 | 471399 |
| **OPERATING EXPENSES** |  |  |
| &nbsp;&nbsp;&nbsp;Cost of operations, excluding depreciation and amortization | 550512 | 453480 |
| &nbsp;&nbsp;&nbsp;Lease abandonment charges |  | 5388 |
| &nbsp;&nbsp;&nbsp;Depreciation and amortization | 44967 | 35483 |
| &nbsp;&nbsp;&nbsp;Loss (gain) on sale and disposal of equipment and other | 2591 | 402 |
| &nbsp;&nbsp;&nbsp;Severance costs | 1464 | 747 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total operating expenses | 599534 | 495500 |
| **INCOME (LOSS) FROM OPERATIONS** | **(23903)** | **(24101)** |
| **OTHER INCOME AND EXPENSES** |  |  |
| &nbsp;&nbsp;&nbsp;Interest expense | 17657 | 17239 |
| &nbsp;&nbsp;&nbsp;Equity in earnings of joint ventures | (3825) | (2599) |
| &nbsp;&nbsp;&nbsp;Non-cash change in fair value of interest rate hedge |  | 2106 |
| &nbsp;&nbsp;&nbsp;Other (income) expenses | (4907) | (7712) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total other (income) expenses | 8925 | 9034 |
| **INCOME (LOSS) BEFORE INCOME TAXES** | **(32828)** | **(33135)** |
| &nbsp;&nbsp;&nbsp;Provision for income taxes | 8096 | 3398 |
| **NET INCOME (LOSS)** | **(24732)** | **(29737)** |
| &nbsp;&nbsp;&nbsp;Net income (loss) attributable to noncontrolling interests | 8734 | 8189 |
| **NET INCOME (LOSS) ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS** | $**(33466)** | $**(37926)** |
| **BASIC NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS** | $**(0.43)** | $**(0.51)** |
| **DILUTED NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS** | $**(0.43)** | $**(0.51)** |
| **WEIGHTED AVERAGE SHARES OUTSTANDING** |  |  |
| &nbsp;&nbsp;&nbsp;Basic | 77057835 | 74382356 |
| &nbsp;&nbsp;&nbsp;Diluted | 77057835 | 74382356 |

---

**RADNET, INC. AND SUBSIDIARIES**

**CONDENSED CONSOLIDATED STATEMENTS OF CASHFLOWS**

**(IN THOUSANDS)**

(unaudited)

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
|  | **2026** | **2025** |
| **CASH FLOWS FROM OPERATING ACTIVITIES** |  |  |
| &nbsp;&nbsp;&nbsp;Net loss | $(24732) | $(29737) |
| &nbsp;&nbsp;&nbsp;Adjustments to reconcile net loss to net cash provided by operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;Depreciation and amortization | 44967 | 35483 |
| &nbsp;&nbsp;&nbsp;Noncash operating lease expense | 16298 | 14431 |
| &nbsp;&nbsp;&nbsp;Equity in earnings of joint ventures, net of dividends | (1069) | (2599) |
| &nbsp;&nbsp;&nbsp;Amortization of deferred financing costs and loan discount | 779 | 728 |
| &nbsp;&nbsp;&nbsp;Loss on sale and disposal of equipment | 2591 | 402 |
| &nbsp;&nbsp;&nbsp;Lease abandonment charges |  | 5388 |
| &nbsp;&nbsp;&nbsp;Amortization of cash flow hedge |  | 1033 |
| &nbsp;&nbsp;&nbsp;Non-cash change in fair value of interest rate swap |  | 2106 |
| &nbsp;&nbsp;&nbsp;Stock-based compensation | 31375 | 28494 |
| &nbsp;&nbsp;&nbsp;Change in fair value of contingent consideration | (2764) |  |
| &nbsp;&nbsp;&nbsp;Changes in operating assets and liabilities, net of assets acquired and liabilities assumed in purchase transactions: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable | 9375 | (14306) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other current assets | (6172) | (7206) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other assets | (660) | (1691) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred taxes | (9099) | 5137 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating leases | (13299) | (21968) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred revenue | 234 | 128 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable, accrued expenses and other | 31148 | 25658 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by operating activities | 78972 | 41481 |
| **CASH FLOWS FROM INVESTING ACTIVITIES** |  |  |
| &nbsp;&nbsp;&nbsp;Purchase of imaging facilities and other acquisitions, net of cash acquired | (304151) | (3794) |
| &nbsp;&nbsp;&nbsp;Purchase of property and equipment and other | (69932) | (48833) |
| &nbsp;&nbsp;&nbsp;Proceeds from sale of equipment | 277 | 23 |
| &nbsp;&nbsp;&nbsp;Equity contributions in existing and purchase of interest in joint ventures |  | (4147) |
| &nbsp;&nbsp;&nbsp;Collection of notes receivable | 2833 | – |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash used in investing activities | (370973) | (56751) |
| **CASH FLOWS FROM FINANCING ACTIVITIES** |  |  |
| &nbsp;&nbsp;&nbsp;Principal payments on notes and leases payable | (9953) | (1718) |
| &nbsp;&nbsp;&nbsp;Payments on Term Loan Debt | (5252) | (5000) |
| &nbsp;&nbsp;&nbsp;Distributions paid to noncontrolling interests | (2402) | (913) |
| &nbsp;&nbsp;&nbsp;Proceeds from issuance of common stock upon exercise of options | 103 | 121 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash used in financing activities | (17504) | (7510) |
| **EFFECT OF EXCHANGE RATE CHANGES ON CASH** | (2371) | 83 |
| **NET DECREASE IN CASH AND CASH EQUIVALENTS** | (311876) | (22697) |
| **CASH AND CASH EQUIVALENTS, beginning of period** | 767215 | 740020 |
| **CASH AND CASH EQUIVALENTS, end of period** | $455339 | $717323 |
| **SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION** |  |  |
| &nbsp;&nbsp;&nbsp;Cash paid during the period for interest | $17073 | $18010 |
| &nbsp;&nbsp;&nbsp;Cash paid during the period for income taxes | $519 | $272 |

---

**RADNET, INC. AND SUBSIDIARIES**

**RECONCILIATION OF GAAP NET INCOME ATTRIBUTABLE TO**

**RADNET, INC. COMMON SHAREHOLDERS TO ADJUSTED EBITDA**

**(IN THOUSANDS)**

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
|  | **2026** | **2025** |
| Net income (loss) attributable to Radnet, Inc. common stockholders | $(33466) | $(37926) |
| Income taxes | (8096) | (3398) |
| Interest expense | 17657 | 17239 |
| Severance costs | 1464 | 747 |
| Depreciation and amortization | 44967 | 35483 |
| Non-cash employee stock-based compensation | 31376 | 28494 |
| Loss (gain) on sale and disposal of equipment and other | 2591 | 402 |
| Non-cash change in fair value of interest rate hedge |  | 2106 |
| Other expenses (income) | (4907) | (7712) |
| Non-Capitalized R&D - DeepHealth Cloud OS & Generative AI | 4560 | 3562 |
| Lease abandonment charges |  | 5388 |
| Non-cash change to contingent consideration | 2764 |  |
| Non-operational rent expenses | 900 | 1342 |
| Acquisition transaction costs | 3454 | 672 |
| **Adjusted EBITDA - Radnet, Inc.** | $63264 | $46399 |
| **<u>NOTE</u>** |  |  |
| Adjusted EBITDA - Imaging Center Segment | 61961 | 42688 |
| Adjusted EBITDA - Digital Health Segment | 1303 | 3711 |

---

**PAYMENTS BY PAYOR CLASS**

---

| | |
|:---|:---|
|  | First Quarter<br>2026 |
| Commercial Insurance | 57.4% |
| Medicare | 23.8% |
| Capitation | 5.3% |
| Medicaid | 2.4% |
| Workers Compensation/Personal Injury | 2.1% |
| Other\* | 8.9% |
| &nbsp;&nbsp;&nbsp;Total | 100.0% |

---

\* Includes management fee, Digital Health unit and Heart Lung Health revenue.

**RADNET PAYMENTS BY MODALITY**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | First Quarter<br>2026 | Full Year<br>2025 | Full Year<br>2024 | Full Year<br>2023 |
| MRI | 37.6% | 37.7% | 37.1% | 36.8% |
| CT | 15.1% | 15.6% | 15.9% | 16.8% |
| PET/CT | 10.4% | 8.8% | 7.2% | 6.4% |
| X-ray | 5.2% | 5.5% | 6.0% | 6.5% |
| Ultrasound | 13.7% | 13.5% | 13.6% | 12.9% |
| Mammography | 14.7% | 15.6% | 16.4% | 16.0% |
| Nuclear Medicine | 0.9% | 0.9% | 1.0% | 0.8% |
| Other | 2.5% | 2.5% | 2.7% | 3.9% |
|  | 100.0% | 100.0% | 100.0% | 100.0% |

---

**PROCEDURES BY MODALITY**\*

---

| | | |
|:---|:---|:---|
|  | First Quarter<br>2026 | First Quarter<br>2025 |
| MRI | 538043 | 447330 |
| CT | 319201 | 271170 |
| PET/CT | 27572 | 20389 |
| Nuclear Medicine | 10395 | 9577 |
| Ultrasound | 718006 | 656427 |
| Mammography | 504761 | 476378 |
| X-ray and Other | 902977 | 861702 |
| &nbsp;&nbsp;&nbsp;Total | 3020955 | 2742973 |

---

\* Volumes include wholly owned and joint venture centers.

**RADNET, INC. AND SUBSIDIARIES**

**SCHEDULE OF ADJUSTED EARNINGS AND EARNINGS PER SHARE <sup>(3)</sup>**

**(IN THOUSANDS EXCEPT SHARE DATA)**

(unaudited)

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended <br>March 31,** | **Three Months Ended <br>March 31,** |
|  | **2026** | **2025<sup>(iv)</sup>** |
| **NET LOSS INCOME ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS** | $(33466) | $(37926) |
| &nbsp;&nbsp;&nbsp;Add Non-cash change in fair value of interest rate hedges (i) |  | 2106 |
| &nbsp;&nbsp;&nbsp;Add Non-operational rent expenses (iii) | 900 | 1342 |
| &nbsp;&nbsp;&nbsp;Add Acquisition transaction costs | 3454 | 672 |
| &nbsp;&nbsp;&nbsp;Add loss on sale and disposal of equipment and other | 2591 | 402 |
| &nbsp;&nbsp;&nbsp;Add Severance costs | 1464 | 747 |
| &nbsp;&nbsp;&nbsp;Add Lease abandonment charges |  | 5388 |
| &nbsp;&nbsp;&nbsp;Add Change to contingent consideration | 2764 |  |
| &nbsp;&nbsp;&nbsp;Add Non-capitalized R&D - DeepHealth cloud OS & generative AI | 4560 | 3562 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total adjustments - loss (gain) | 15733 | 14219 |
| &nbsp;&nbsp;&nbsp;Subtract tax impact of Adjustments (ii) | (3880) | (1459) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tax effected impact of adjustments | 11853 | 12760 |
| **TOTAL ADJUSTMENT TO NET INCOME (LOSS) ATTRIBUTABLE TO RADNET, INC. COMMON SHAREHOLDERS** | 11853 | 12760 |
| **ADJUSTED NET LOSS ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS** | $(21613) | $(25166) |
| **WEIGHTED AVERAGE SHARES OUTSTANDING** |  |  |
| &nbsp;&nbsp;&nbsp;Diluted | 77057835 | 74382356 |
| **ADJUSTED DILUTED NET LOSS PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS** | $(0.28) | $(0.34) |

---

(i) Impact from the change in fair value of
the hedges during the quarter. Excludes the amortization of the accumulation of the changes in fair value out of Other
Comprehensive Income that existed prior to the hedges becoming ineffective.

(ii) Tax effected using 10.26% and 24.66%
blended federal and state effective tax rate for the first quarter of 2025 and 2026, respectively.

(iii) Represents rent expense associated with de novo sites under construction prior to them becoming operational.

(iv) Adjusted from what was reported during
last year's fourth quarter for an additional addback of $402,000 Loss on the Sale and Disposal of Equipment and Other and $747,000
Severance Costs.

<u>Footnotes</u>

<sup>(1)</sup> The Company defines Adjusted EBITDA as earnings before interest, taxes, depreciation and amortization, each from continuing operations and adjusted for losses or gains on the sale of equipment, other income or loss, debt extinguishments and non-cash equity compensation. Adjusted EBITDA includes equity earnings in unconsolidated operations and subtracts allocations of earnings to non-controlling interests in subsidiaries, and is adjusted for non-cash or extraordinary and one-time events taken place during the period.

Adjusted EBITDA is reconciled to its nearest comparable GAAP financial measure. Adjusted EBITDA is a non-GAAP financial measure used as analytical indicator by RadNet management and the healthcare industry to assess business performance, and is a measure of leverage capacity and ability to service debt. Adjusted EBITDA should not be considered a measure of financial performance under GAAP, and the items excluded from Adjusted EBITDA should not be considered in isolation or as alternatives to net income, cash flows generated by operating, investing or financing activities or other financial statement data presented in the consolidated financial statements as an indicator of financial performance or liquidity. As Adjusted EBITDA is not a measurement determined in accordance with GAAP and is therefore susceptible to varying methods of calculation, this metric, as presented, may not be comparable to other similarly titled measures of other companies.

<sup>(2)</sup> As noted above, the Company defines Free Cash Flow as Adjusted EBITDA less total Capital Expenditures (whether completed with cash or financed) and Cash Interest paid. Free Cash Flow is a non-GAAP financial measure. The Company uses Free Cash Flow because the Company believes it provides useful information for investors and management because it measures our capacity to generate cash from our operating activities. Free Cash Flow does not represent total cash flow since it does not include the cash flows generated by or used in financing activities. In addition, our definition of Free Cash Flow may differ from definitions used by other companies.

Free Cash Flow should not be considered a measure of financial performance under GAAP, and the items excluded from Adjusted EBITDA should not be considered in isolation or as alternatives to net income, cash flows generated by operating, investing or financing activities or other financial statement data presented in the consolidated financial statements as an indicator of financial performance or liquidity. As Adjusted EBITDA is not a measurement determined in accordance with GAAP and is therefore susceptible to varying methods of calculation, this metric, as presented, may not be comparable to other similarly titled measures of other companies.

<sup>(3)</sup> The Company defines Adjusted Earnings (Loss) Per Share as net income or loss attributable to RadNet, Inc. common stockholders and excludes losses or gains on the disposal of equipment, loss on debt extinguishments, bargain purchase gains, severance costs, loss on impairment, loss or gain on swap valuation, gain on extinguishment of debt, unusual or non-recurring entries that impact the Company's tax provision and any other non-recurring or unusual transactions recorded during the period.

Adjusted Earnings (Loss) Per Share is reconciled to its nearest comparable GAAP financial measure. Adjusted Earnings (Loss) Per Share is a non-GAAP financial measure used as analytical indicator by RadNet management and the healthcare industry to assess business performance. Adjusted Earnings Per Share should not be considered a measure of financial performance under GAAP, and the items excluded from Adjusted Earnings Per Share should not be considered in isolation or as alternatives to net income, cash flows generated by operating, investing or financing activities or other financial statement data presented in the consolidated financial statements as an indicator of financial performance or liquidity. As Adjusted Earnings Per Share is not a measurement determined in accordance with GAAP and is therefore susceptible to varying methods of calculation, this metric, as presented, may not be comparable to other similarly titled measures of other companies.

<sup>(4)</sup> The Company defines Annual Recurring Revenue (ARR) as a key subscription economy metric representing the predictable, normalized annualized value of contracted recurring revenue generated from customers from active customer contracts. ARR includes subscription fees, recurring support fees, and contracted usage charges and excludes one-time, non-recurring fees such as, implementation, hardware sales, professional services, consulting and one-off training. ARR is a non-GAAP measure and does not represent GAAP revenue recognized over time.